Citation Impact
Citing Papers
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
2003 Science
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Directed evolution of cytochrome c for carbon–silicon bond formation: Bringing silicon to life
2016 StandoutScienceNobel
A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF
2001 StandoutScience
Adaptive Therapy
2009
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
2004 Standout
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Hallmarks of Cancer: The Next Generation
2011 Standout
Endogenous human microRNAs that suppress breast cancer metastasis
2008 StandoutNature
Inflammation and cancer
2002 StandoutNature
Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme
1994
A view on drug resistance in cancer
2019 StandoutNature
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Clinical translation of angiogenesis inhibitors
2002 Standout
Signal transduction by cGMP-dependent protein kinases and their emerging roles in the regulation of cell adhesion and gene expression
2005
Oncogenic kinase signalling
2001 StandoutNature
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
2007 Nature
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
2002
Molecular Basis of Vascular Anomalies
1998
Tumor angiogenesis: past, present and the near future
2000
Adhesion events in angiogenesis
2001
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
2014 StandoutNature
Antiangiogenic agents
1999
Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
1999
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
1992 StandoutNature
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Hallmarks of Cancer
2000 Standout
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
1997 Standout
Nuclear factor-κB in cancer development and progression
2006 StandoutNature
The urokinase-type plasminogen activator system in cancer metastasis: A review
1997 Standout
Prostaglandin E2 Induces Hypoxia-inducible Factor-1α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line
2002
Angiogenesis in life, disease and medicine
2005 StandoutNature
The microenvironment of the tumour–host interface
2001 StandoutNature
Immunity, Inflammation, and Cancer
2010 Standout
Maspin is an angiogenesis inhibitor
2000 Standout
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors
2004
Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase
2000 Nature
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Vascular-specific growth factors and blood vessel formation
2000 StandoutNature
Mechanisms of angiogenesis
1997 StandoutNature
Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
2005
Differential Expression of Vascular Endothelial Growth Factor–A Isoforms at Different Stages of Melanoma Progression
2003
Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth
2001
Transgenic mouse models in angiogenesis and cardiovascular disease
2000
Targeting autophagy in cancer
2017 Standout
Elevated copper and oxidative stress in cancer cells as a target for cancer treatment
2008
Clonal evolution in cancer
2012 StandoutNature
The Hallmarks of Aging
2013 Standout
Analysis of experimental antiangiogenic therapy
1993
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
2000
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
2001
Angiogenesis as a therapeutic target
2005 StandoutNature
Inferences, questions and possibilities in Toll-like receptor signalling
2004 StandoutNatureNobel
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
1993 StandoutNature
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
2000
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
1999
A systems approach to cancer therapy
1996
Radiation therapy to a primary tumor accelerates metastatic growth in mice.
2001
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
The generation of endostatin is mediated by elastase.
1999
Generation of multiple angiogenesis inhibitors by human pancreatic cancer.
2001
CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells
1997
Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
2000 StandoutNobel
Organosilicon Molecules with Medicinal Applications
2012
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Genes and pathways downstream of telomerase in melanoma metastasis
2006 StandoutNobel
Role of angiogenesis in tumor growth and metastasis
2002 Standout
Posttranslational hydroxylation of ankyrin repeats in IκB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH)
2006 StandoutNobel
Angiostatin binds ATP synthase on the surface of human endothelial cells
1999
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction.
2000
Stapled Peptide Inhibitors of Autophagy Adapter LC3B
2020
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
1999
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
2001
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
2002
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
2005
Spatiotemporal dynamics of guanosine 3′,5′-cyclic monophosphate revealed by a genetically encoded, fluorescent indicator
2001 StandoutNobel
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
1997 StandoutNobel
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Regulation of Mammalian O2Homeostasis by Hypoxia-Inducible Factor 1
1999 StandoutNobel
Bioavailable copper modulates oxidative phosphorylation and growth of tumors
2013
Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
2001
Angiogenesis in Endocrine Tumors
2003
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Stapled β-Hairpins Featuring 4-Mercaptoproline
2021 StandoutNobel
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
2001
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
2000
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of Stephen Gately being referenced
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
1995
Immunolocalization of basic fibroblast growth factor to the micro vasculature of human brain tumors
1992
The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis
2000
Therapeutic Potential of Selective Cyclooxygenase-2 Inhibitors in the Management of Tumor Angiogenesis
2003
Combined effects of angiostatin and ionizing radiation in antitumour therapy
1998 Nature
Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP.
1997
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy
2004
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
2014
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
1999
Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin.
1998
Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds
2007
Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
1996
Synthesis of lipophilic sila derivatives of N‐acetylcysteineamide, a cell permeating thiol
2009
Antiangiogenic scheduling of lower dose cancer chemotherapy.
2002
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
1997
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
1999
Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo.
1997
Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.
1990
Synthesis of Improved Lysomotropic Autophagy Inhibitors
2015
Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
1994